Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial OfficerBusiness Wire • 09/09/24
Geron Corporation Reports Second Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 08/08/24
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDSBusiness Wire • 07/26/24
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024Business Wire • 07/23/24
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood CancersInvestopedia • 06/07/24
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaBusiness Wire • 06/07/24
Geron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 05/02/24